JPH09501939A - クローン病および潰瘍性大腸炎の標的処置のための医薬組成物 - Google Patents
クローン病および潰瘍性大腸炎の標的処置のための医薬組成物Info
- Publication number
- JPH09501939A JPH09501939A JP7507896A JP50789695A JPH09501939A JP H09501939 A JPH09501939 A JP H09501939A JP 7507896 A JP7507896 A JP 7507896A JP 50789695 A JP50789695 A JP 50789695A JP H09501939 A JPH09501939 A JP H09501939A
- Authority
- JP
- Japan
- Prior art keywords
- active agent
- capsules
- capsule
- cellulose acetate
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.1種または数種のポリマーフィルムで被覆されている澱粉カプセルまたは 硬または軟ゼラチンカプセル内に溶解された形の免疫抑制活性剤を含む、医薬製 剤。 2.活性剤としてラパマイシン、タクロリムス、サイクロスポリンAまたはこ れらの活性剤の組み合わせを含むことを特徴とする、請求項1記載の医薬製剤。 3.カプセルコーティングが、セルロース誘導体、メタクリル酸誘導体、ポリ ビニル誘導体およびこれらの混合物から選択されたポリマーから成ることを特徴 とする、請求項1または2記載の医薬製剤。 4.硬または軟ゼラチンカプセルが、メチルセルロース、エチルセルロース、 セルロースアセテート、セルロースアセテートブチレート、セルロースアセテー トフタレート、セルロースアセテートトリメリテート、セルロースアセテートプ ロピオネート、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセル ロース、ヒドロキプロピルメチルセルロースフタレート、ヒドロキシプロピルメ チルセルロースアセテートサクシネート、ポリビニルアルコール、ポリビニルア セテート、ポリビニルアセテートフタレート、メチルアクリレート/メチルメタ クリレートコポリマー、メタクリル酸/エチルアクリートコポリマー、ポリメチ ルビニルエーテル/マロン酸無水物コポリマー、ポリメチルビニルエーテル/マ ロン酸−エチル、−イソプロピル、−n−ブチルエステルコポリマーまたはこれ らの混合物から成る、1種のポリマーフィルムまたは数種のポリマーフィルムで 被覆されていることを特徴とする、請求項1、2または3項のいずれかに記載の 医薬製剤。 5.カプセルに含まれる溶液中の活性剤の濃度(w/w)が、0.2から20%、 好ましくは1から15%、特に好ましくは2から10%の範囲にあることを特徴 とする、請求項1から4のいずれかに記載の医薬製剤。 6.溶解活性剤が、ヒト小および/または大腸領域でカプセルから放出される ことを特徴とする、請求項1から5のいずれかに記載の医薬製剤。 7.クローン病および潰瘍性大腸炎の処置のための、請求項1から6のいずれ かに記載の医薬製剤。 8.活性剤を、澱粉またはゼラチンカプセル内に包含させるのに好適な溶媒ま たは数種の溶媒および他の添加剤の混合物に溶解し、溶液を、次いでそれ自身既 知の方法で澱粉カプセルまたは硬または軟ゼラチンカプセルに正確な用量を充填 し、カプセルを封印し、カプセルをポリマーまたはポリマー混合物の溶液または 分散剤で被覆し、乾燥する(ここで、コーティング工程は1回または数回反復し てもよい)ことを特徴とする、請求項1から6のいずれかに記載の医薬製剤の製 造法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4329503A DE4329503A1 (de) | 1993-09-01 | 1993-09-01 | Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa |
DE4329503.7 | 1993-09-01 | ||
PCT/EP1994/002643 WO1995006464A1 (de) | 1993-09-01 | 1994-08-10 | Pharmazeutische präparate zur gezielten behandlung von morbus crohn und colitis ulcerosa |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09501939A true JPH09501939A (ja) | 1997-02-25 |
JP3712005B2 JP3712005B2 (ja) | 2005-11-02 |
Family
ID=6496579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50789695A Expired - Fee Related JP3712005B2 (ja) | 1993-09-01 | 1994-08-10 | クローン病および潰瘍性大腸炎の標的処置のための医薬組成物 |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP0716598B1 (ja) |
JP (1) | JP3712005B2 (ja) |
AT (1) | ATE207743T1 (ja) |
AU (1) | AU693470B2 (ja) |
CA (1) | CA2170748C (ja) |
CY (1) | CY2340B1 (ja) |
DE (2) | DE4329503A1 (ja) |
DK (1) | DK0716598T3 (ja) |
ES (1) | ES2166781T3 (ja) |
NZ (1) | NZ271655A (ja) |
PT (1) | PT716598E (ja) |
WO (1) | WO1995006464A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999049863A1 (fr) * | 1998-03-26 | 1999-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Preparations a liberation prolongee |
JP2002525314A (ja) * | 1998-09-28 | 2002-08-13 | ワーナー−ランバート・カンパニー | Hpmcカプセルを使用する腸及び結腸への送達 |
JP2010523555A (ja) * | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | 「経口医薬組成物」 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
ES2124926T3 (es) * | 1994-03-22 | 1999-02-16 | Nippon Kayaku Kk | Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas. |
GB2303550B (en) * | 1994-06-21 | 1998-07-08 | Danbiosyst Uk | Colonic drug delivery system |
GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
WO1998046268A1 (fr) * | 1997-04-11 | 1998-10-22 | Fujisawa Pharmaceutical Co., Ltd. | Composition medicamenteuse |
US6030641A (en) * | 1997-06-03 | 2000-02-29 | Uni Colloid Kabushiki Kaisha | Sustained release capsule and method for preparing the same |
AUPP584198A0 (en) * | 1998-09-14 | 1998-10-08 | Fujisawa Pharmaceutical Co., Ltd. | New use |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
GB0525546D0 (en) * | 2005-12-15 | 2006-01-25 | Novartis Ag | Organic compounds |
JP2010527285A (ja) | 2007-04-26 | 2010-08-12 | シグモイド・ファーマ・リミテッド | 複数のミニカプセルの製造 |
FR2933871B1 (fr) * | 2008-07-18 | 2012-12-14 | Yvery | Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe |
WO2010122574A2 (en) * | 2009-04-20 | 2010-10-28 | Sun Pharma Advanced Research Company Ltd. | Coated capsule |
EP3300723A1 (en) | 2009-05-18 | 2018-04-04 | Sigmoid Pharma Limited | Composition comprising oil drops |
JP5911799B2 (ja) | 2009-08-12 | 2016-04-27 | シグモイド・ファーマ・リミテッドSigmoid Pharma Limited | ポリマーマトリックスおよび油相を含んで成る免疫調節組成物 |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
EP3215127B1 (en) | 2014-11-07 | 2020-10-28 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
US20210113479A1 (en) * | 2018-05-03 | 2021-04-22 | M.W. Encap Limited | Dosage forms for delivery of medicines to the lower gastrointestinal tract |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2340060A1 (de) * | 1973-08-08 | 1975-02-20 | Scherer Gmbh R P | Magensaftresistente gelatinekapseln und verfahren zu deren herstellung |
BE895724A (fr) * | 1982-02-01 | 1983-07-28 | Sandoz Sa | Nouvelle utilisation therapeutique de la dihydrocyclosporine d |
SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
IL77186A0 (en) * | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
JPH0211514A (ja) * | 1988-06-30 | 1990-01-16 | Takara Shuzo Co Ltd | スパガリン類製剤 |
US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
-
1993
- 1993-09-01 DE DE4329503A patent/DE4329503A1/de not_active Withdrawn
-
1994
- 1994-08-10 AU AU75354/94A patent/AU693470B2/en not_active Ceased
- 1994-08-10 ES ES94925443T patent/ES2166781T3/es not_active Expired - Lifetime
- 1994-08-10 JP JP50789695A patent/JP3712005B2/ja not_active Expired - Fee Related
- 1994-08-10 CA CA002170748A patent/CA2170748C/en not_active Expired - Fee Related
- 1994-08-10 DK DK94925443T patent/DK0716598T3/da active
- 1994-08-10 PT PT94925443T patent/PT716598E/pt unknown
- 1994-08-10 EP EP94925443A patent/EP0716598B1/de not_active Expired - Lifetime
- 1994-08-10 NZ NZ271655A patent/NZ271655A/en not_active IP Right Cessation
- 1994-08-10 DE DE59409929T patent/DE59409929D1/de not_active Expired - Fee Related
- 1994-08-10 WO PCT/EP1994/002643 patent/WO1995006464A1/de active IP Right Grant
- 1994-08-10 AT AT94925443T patent/ATE207743T1/de not_active IP Right Cessation
- 1994-08-10 EP EP01108141A patent/EP1110545A3/de not_active Withdrawn
-
2003
- 2003-03-18 CY CY0300027A patent/CY2340B1/xx unknown
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999049863A1 (fr) * | 1998-03-26 | 1999-10-07 | Fujisawa Pharmaceutical Co., Ltd. | Preparations a liberation prolongee |
US6440458B1 (en) | 1998-03-26 | 2002-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release preparations |
US6576259B2 (en) | 1998-03-26 | 2003-06-10 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release formulations containing tacrolimus |
US6884433B2 (en) | 1998-03-26 | 2005-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release formulation containing tacrolimus |
US8551522B2 (en) | 1998-03-26 | 2013-10-08 | Astellas Pharma Inc. | Sustained-release formulation |
JP2002525314A (ja) * | 1998-09-28 | 2002-08-13 | ワーナー−ランバート・カンパニー | Hpmcカプセルを使用する腸及び結腸への送達 |
JP2010523555A (ja) * | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | 「経口医薬組成物」 |
JP2010523553A (ja) * | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | シクロスポリン医薬組成物 |
JP2014196368A (ja) * | 2007-04-04 | 2014-10-16 | シグモイド・ファーマ・リミテッドSigmoid Pharma Limited | 「経口医薬組成物」 |
JP2017160241A (ja) * | 2007-04-04 | 2017-09-14 | シグモイド・ファーマ・リミテッドSigmoid Pharma Limited | 「経口医薬組成物」 |
Also Published As
Publication number | Publication date |
---|---|
AU693470B2 (en) | 1998-07-02 |
CA2170748A1 (en) | 1995-03-09 |
EP0716598B1 (de) | 2001-10-31 |
DK0716598T3 (da) | 2002-02-18 |
AU7535494A (en) | 1995-03-22 |
NZ271655A (en) | 1997-09-22 |
PT716598E (pt) | 2002-04-29 |
EP1110545A2 (de) | 2001-06-27 |
JP3712005B2 (ja) | 2005-11-02 |
ES2166781T3 (es) | 2002-05-01 |
WO1995006464A1 (de) | 1995-03-09 |
EP1110545A3 (de) | 2001-07-04 |
CY2340B1 (en) | 2004-02-06 |
CA2170748C (en) | 2008-10-28 |
DE4329503A1 (de) | 1995-03-02 |
ATE207743T1 (de) | 2001-11-15 |
EP0716598A1 (de) | 1996-06-19 |
DE59409929D1 (de) | 2001-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3712005B2 (ja) | クローン病および潰瘍性大腸炎の標的処置のための医薬組成物 | |
US6503883B1 (en) | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis | |
US5316772A (en) | Bilayered oral pharmaceutical composition with pH dependent release | |
KR0140985B1 (ko) | 장기 작용성 제제에 유용한 약물 방출 조절용 피복물질 | |
JP3194974B2 (ja) | 標的制御釈放薬剤 | |
HU216836B (hu) | Eljárás gyulladásos jellegű bélbetegségek kezelésére alkalmas, budezonidot tartalmazó, perorális gyógyszerkészítmények előállítására | |
JP2002527468A (ja) | 脈動用量薬剤経口送達システム | |
BRPI0809563A2 (pt) | Formas de dosagem modificadas de tacrolimus | |
US5277916A (en) | Tetracycline dosage form | |
CZ296964B6 (cs) | Farmaceutické formulace tramadolu v násobných jednotkách a zpusob jejich výroby | |
CA2121038C (en) | Oral preparation for release in lower digestive tracts | |
AU727152B2 (en) | Delayed-release dosage forms of sertraline | |
CA2032475C (en) | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines | |
JPH0710745A (ja) | 放出開始時間制御型腸デリバリー経口製剤 | |
WO2017150803A1 (ko) | 에소메프라졸을 포함하는 제제 | |
US5258186A (en) | Drug release controlling coating material for long acting formulations | |
JP4711499B2 (ja) | 多細孔性食物防護 | |
JPH04264022A (ja) | 下部消化管放出型経口製剤 | |
US20210113479A1 (en) | Dosage forms for delivery of medicines to the lower gastrointestinal tract | |
MXPA99012082A (en) | Delayed-release dosage forms of sertraline | |
MXPA06004017A (es) | Formas de dosis una vez al dia de trospio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040713 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040707 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041012 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050603 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050726 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050809 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080826 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090826 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |